Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

M A Hoechstetter,R Busch,Barbara Eichhorst,Andreas Bühler,Dirk Winkler,Michael J. Eckart,Ursula Vehling-Kaiser,H. Schimke,Ulrich Jäger,Hans Juergen Hurtz,Georg Hopfinger,F Hartmann,H. Fuss,Wolfgang Abenhardt,I. Blau,W. Freier,Lothar Müller,Mariele Goebeler,Wendtner Cm,Jasmin Bahlo,Konstanze Fischer,Martin Bentz,Bertold Emmerich,H Döhner,Michael Hallek,S. Stilgenbauer

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

2017

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Keywords:

Chronic lymphocytic leukemia
Cancer research
Oncology
Vidarabine
German
Biology
Internal medicine
Fludarabine
disease free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations